C. difficile 위험도


Mild or moderate infectionSevere infectionBacterial meningitis, endocarditis500 mg IV q4h1 g IV q4h2 g IV q4h (max 12 g/d)No renal dose adjustment

  • Age <1m 20 mg/kg IV #2

  • Age ≥1m 50 mg/kg IV #2

  • BW >40 kg Refer to adult dose

  • Age <1w 75 mg/kg IV #2-3

  • Age 1w-1m 100-150 mg/kg IV #3-4

  • Age >1m 200 mg/kg IV #4

  • BW >40 kg Refer to adult dose

No renal dose adjustment

Patients with hepatic insufficiency and renal failure: Serum nafcillin levels should be measured and dosage adjusted accordingly

General Information

Treatment of MSSA infections

Infective endocarditis, Oxacillin-susceptible staphylococci

Staphylococcal infectious disease, penicillinase-producing staphylococci

Monitor baseline and periodic CBC with differential.

Monitor liver and renal functions.

  • Phlebitis at injection site

  • C. difficile colitis

  • Hypokalemia

  • Agranulocytosis

  • Bone marrow depression

  • Tubulointerstitial nephritis

  • Abnormal liver enzymes

  • CYP3A/4 inducers

  • Warfarin- decreased PT/INR

  • Cyclosporine- decreases serum concentrations

  • Tetracyclines

Antimicrobial class: Antistaphylococcal penicillin

Pregnancy category: B

Average serum half life: 0.5-1 hr

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Route of Elimination: Primarily hepatic


  • Use caution in patients with concomitant hepatic insufficiency and renal dysfunction, sensitivity to allergens or history of asthma.

  • Discontinuation of Clostridium difficile associated diarrhea may be necessary.

Attribution: Antimicrobial information adapted from Dignity Health (Bakersfield Hospital)

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.